Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients

The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS ... data expected from our ongoing trials, we are confident in our ability to reali...

Bitcoin bloodbath continues as it drops below $6k mark – and Barclays investment expert warns 'the rout in cryptocurrencies is still not finished'

We continue to argue that without a role in the global economy, the intrinsic value ... There are reports that this has proved hard for some people. A time of market stress could lead to people being ...